Patent application EP16175382A (EP), filed 2016-06-21
Publication number: EP3260133A1
Title: ANTIBODIES AGAINST MAC-1
Abstract: [0001]    The present invention provides an isolated monoclonal antibody or an antigen-binding portion thereof which
a) binds to Mac-1,
b) specifically inhibits the interaction of CD40L with activated Mac-1 and
c) does not induce integrin outside-in signaling.
IPC codes: A61K  39/    00            A I
A61P  17/    02            A I
A61P  31/    04            A I
A61P   9/    10            A I
C07K  16/    28            A I
Claims: number: 1
text: An isolated monoclonal antibody or an antigen-binding portion thereof which
number: 2
text: Isolated monoclonal antibody or antigen-binding portion thereof according to claim 1 characterized in that it does not bind to non-activated Mac-1.
number: 3
text: Isolated monoclonal antibody or antigen-binding portion thereof according to claim 1 or 2 characterized in that it limits the expression of inflammatory cytokines.
number: 4
text: Isolated monoclonal antibody or antigen-binding portion thereof according to any of claims 1-3 characterized in that it blocks leukocyte recruitment in vitro and in vivo in intravital microscopy.
number: 5
text: Isolated monoclonal antibody or antigen-binding portion thereof according to any of claims 1-4 characterized in that it does not affect thrombotic and hemostatic functions of Mac-1.
number: 6
text: Isolated monoclonal antibody or antigen-binding portion thereof according to any of claims 1-5 characterized in that it comprises at least three CDRs selected from the group consisting of SEQ ID NOs:2-4 and SEQ ID NOs:6-8.
number: 7
text: Isolated monoclonal antibody or antigen-binding portion thereof according to any of claims 1-5 characterized in that it comprises at least four CDRs selected from the group consisting of SEQ ID NOs:2-4 and SEQ ID NOs:6-8.
number: 8
text: Isolated monoclonal antibody or antigen-binding portion thereof according to any of claims 1-5 characterized in that it comprises at least five CDRs selected from the group consisting of SEQ ID NOs:2-4 and SEQ ID NOs:6-8.
number: 9
text: Isolated monoclonal antibody or antigen-binding portion thereof according to any of claims 1-5 characterized in that it comprises six CDRs selected from the group consisting of SEQ ID NOs:2-4 and SEQ ID NOs:6-8.
number: 10
text: Isolated monoclonal antibody or antigen-binding portion thereof according to claim 1 characterized in that the light chain has an identity of at least 80% to the amino acid sequence of SEQ ID NO:1 and that the heavy chain has at least 80% identity to the amino acid sequence of SEQ ID NO:5.
number: 11
text: Isolated monoclonal antibody or antigen-binding portion thereof according to claim 1 characterized in that the light chain has the amino acid sequence of SEQ ID NO:1.
number: 12
text: Isolated monoclonal antibody or antigen-binding portion thereof according to claim 1 characterized in that the amino acid sequence of the heavy chain corresponds to SEQ ID NO:5.
number: 13
text: Isolated monoclonal antibody or antigen-binding portion thereof characterized in that it is selected from the group comprising F<ab> fragments, single chain antibodies, diabodies and/or nanobodies.
number: 14
text: Pharmaceutical composition characterized in that it comprises a pharmaceutically active amount of an antibody or antigen-binding portion thereof according to any of claims 1-13.
number: 15
text: Pharmaceutical composition according to claim 14 for use in the treatment of inflammation.
Office action: search_report, dated 2017-12-27
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: - HOLLIGER ET AL., NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1126 - 1136
ref_type: npl
severity: background
ref_id: - LI ET AL., JOURNAL OF IMMUNOLOGY, 2013, pages 4371 - 4381
ref_type: npl
severity: background
ref_id: EP2444101A1
ref_type: patent
severity: background
ref_id: - HERMANN BLANKENBACH: "Generierung und Charakterisierung eines neuen Liganden-und Aktivitäts-spezifischen Antikörpers zur selektiven Hemmung der CD40L/Mac-1 Interaktion", 27 June 2016 (2016-06-27), XP055289386, Retrieved from the Internet <URL:https://www.freidok.uni-freiburg.de/fedora/objects/freidok:11075/datastreams/FILE1/content> [retrieved on 20160718]
ref_type: npl
severity: background
ref_id: - HERMANN BLANKENBACH: "Generierung und Charakterisierung eines neuen Liganden- und Aktivitäts-spezifischen Antikörpers zur selektiven Hemmung der CD40L/Mac-1 Interaktion Web Page", 27 June 2016 (2016-06-27), XP055289384, Retrieved from the Internet <URL:https://www.freidok.uni-freiburg.de/data/11075> [retrieved on 20160718]
* the whole document *
ref_type: npl
severity: background
ref_id: - D. WOLF ET AL: "Binding of CD40L to Mac-1's I-Domain Involves the EQLKKSKTL Motif and Mediates Leukocyte Recruitment and Atherosclerosis--But Does Not Affect Immunity and Thrombosis in Mice", CIRCULATION RESEARCH., vol. 109, no. 11, 11 November 2011 (2011-11-11), US, pages 1269 - 1279, XP055289391, ISSN: 0009-7330, DOI: 10.1161/CIRCRESAHA.111.247684
ref_type: npl
severity: background
ref_id: EP2444101
ref_type: patent
severity: novelty_destroying
ref_id: - Hermann Blankenbach, "Generierung und Charakterisierung eines neuen Liganden-und Aktivitäts-spezifischen Antikörpers zur selektiven Hemmung der CD40L/Mac-1 Interaktion", (20160627), URL: https://www.freidok.uni-freiburg.de/fedora/objects/freidok:11075/datastreams/FILE1/content, (20160718), XP055289386 [T] 1-15 * the whole document *
ref_type: npl
severity: background
ref_id: [ ]     - Hermann Blankenbach, "Generierung und Charakterisierung eines neuen Liganden- und Aktivitäts-spezifischen Antikörpers zur selektiven Hemmung der CD40L/Mac-1 Interaktion Web Page", (20160627), URL: https://www.freidok.uni-freiburg.de/data/11075, (20160718), XP055289384 [ ] * the whole document *
ref_type: npl
severity: background
ref_id: - D. WOLF ET AL, "Binding of CD40L to Mac-1's I-Domain Involves the EQLKKSKTL Motif and Mediates Leukocyte Recruitment and Atherosclerosis--But Does Not Affect Immunity and Thrombosis in Mice", CIRCULATION RESEARCH., US, (20111111), vol. 109, no. 11, doi:10.1161/CIRCRESAHA.111.247684, ISSN 0009-7330, pages 1269 - 1279, XP055289391 [A] 1-15 * the whole document *
ref_type: npl
severity: background
Final disposition: pending (2017-12-27)